ZYGK1
/ Zydus Lifesci
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
June 27, 2025
Evaluation of Repeat Dose Toxicity and Embryo-Fetal Developmental Toxicity of Novel Glucokinase Activator ZYGK1 in Wistar Rats.
(PubMed, Int J Toxicol)
- "Treatment from GD 6 to 15 caused no significant fetal abnormalities, except incidental fetal skeleton anomalies. Thus, ZYGK1 may lead to maternal hypoglycemia, but no significant developmental toxicity was observed."
Journal • Preclinical • Hypoglycemia
February 24, 2025
Pharmacological effect of ZYGK1, a novel glucokinase activator, in hyperglycemic and sulfonylurea-resistant type 2 diabetes in mice models.
(PubMed, J Diabetes Complications)
- "ZYGK1 appears to be a potential therapeutic option for the treatment of type 2 diabetes owing to its action in the liver and pancreas, and in conditions resistant to sulfonylurea therapy."
Journal • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
January 25, 2021
"E*TRADE Wins Top Spot for Options Trading, Trader App, and Web Trading Platform by https://t.co/NjrmJOwoyK https://t.co/bf9FzyGK1B"
(@NewsFromBW)
1 to 3
Of
3
Go to page
1